These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16815546)

  • 1. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.
    Laurenti L; Piccioni P; Tarnani M; De Padua L; Garzia M; Efremov DG; Piccirillo N; Chiusolo P; Sica S; Leone G
    Leuk Res; 2007 Feb; 31(2):253-6. PubMed ID: 16815546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.
    Giannopoulos K; Dmoszyńska A; Roliński J
    Leuk Res; 2007 Mar; 31(3):411-2. PubMed ID: 16978694
    [No Abstract]   [Full Text] [Related]  

  • 3. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
    Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
    Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
    Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
    Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
    Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
    J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia.
    Forconi F; Fabbri A; Lenoci M; Sozzi E; Gozzetti A; Tassi M; Raspadori D; Lauria F
    Hematol Oncol; 2008 Dec; 26(4):247-51. PubMed ID: 18642397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
    Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
    Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
    J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
    Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.
    Giannopoulos K; Dmoszynska A; Kowal M; Wasik-Szczepanek E; Bojarska-Junak A; Rolinski J; Döhner H; Stilgenbauer S; Bullinger L
    Leukemia; 2009 Oct; 23(10):1771-8. PubMed ID: 19440214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
    Eichhorst BF; Busch R; Obwandner T; Kuhn-Hallek I; Herschbach P; Hallek M;
    J Clin Oncol; 2007 May; 25(13):1722-31. PubMed ID: 17389338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome.
    Laurenti L; De Padua L; Tarnani M; Piccirillo N; Falcucci P; D'Arena G; Innocenti I; Marietti S; Efremov DG; Chiusolo P; Zini G; Sora' F; Sica S; Leone G
    Ann Hematol; 2011 Jan; 90(1):59-65. PubMed ID: 20625902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
    Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
    Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
    Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
    Kasamon YL; Flinn IW; Grever MR; Diehl LF; Garrett-Mayer E; Goodman SN; Lucas MS; Byrd JC
    Clin Cancer Res; 2005 Dec; 11(23):8413-7. PubMed ID: 16322303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
    J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia.
    MacCallum S; Groves M; Brass D; Cunningham J; Sales M; Gelly K; Tauro S
    J Clin Pathol; 2009 May; 62(5):468-70. PubMed ID: 19398596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.